Clinical trial
Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in…
NCT02092350 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT02092350 |
|---|---|
| Title | Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052) |
| Official title | A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic Hepatitis C Virus Infection and Chronic Kidney Disease |
| Acronym | C-SURFER |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis C Virus |
| Intervention type | Drug |
| Interventions | Grazoprevir, Elbasvir, Placebo to Grazoprevir, Placebo to Elbasvir |
| Enrollment | 237 |
| Start date | Mar 17, 2014 |
| Primary completion | Mar 11, 2015 |
| Completion | Sep 2, 2015 |
| First posted | Mar 20, 2014 |
| Last update posted | Sep 24, 2018 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: